ClinicalTrials.gg
CompletedNCT00689416Updated Jun 30, 2009

Effects of Crestor on Inflammation of Atherosclerotic Plaques

An Early Phase 1 interventional study of rosuvastatin and placebo in Atherosclerosis and Inflammatory Activity in Carotid Arteries, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-30.

Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.

Planned enrollment
13th of 24
74 · median 77
Started
2007
with 2 others
Phase 1
3 of 25
none open now
Registered
8th of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 13th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 1, and was the 8th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing rosuvastatin in Atherosclerosis, or all of them as a file.
02

Study summary

The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these techniques are promising for future proof of principle studies. A number of patients will receive placebo as a control.

03

Conditions studied

  • Atherosclerosis
  • Inflammatory Activity in Carotid Arteries

Browse trials for

Keywords

  • imaging biomarkers
  • MRI
  • FDG-PET/CT scanning
  • Crestor
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a non-calcified plaque of at least 2 mm over an at least 6 mm length on first MR scan with an uptake of contrast agent on the dynamic MRI scan
  • Signed written .
  • Healthy men 18 - 70 years, women 60 - 70

Exclusion criteria

Exclusion Criteria:

  • Use of a statin within six months before randomization.
  • Use of lipid altering medication other than statins within the last six months.
  • Clinical evidence of metabolic or vascular disease requiring statin or other lipid lowering pharmacological or non-pharmacological treatment.
  • Total cholesterol > 8, LDL-C > 6 or TG > 6 mmol/L at enrolment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    1

    Drug: rosuvastatin

  • Placebo comparator
    2

    Drug: placebo

Interventions

  • 40 mg, tablet, once daily for 3 months.

    Also known as: Crestor

  • Drugplacebo

    40 mg, tablet, once daily for 3 months

06

What researchers measure

Primary outcomes

  1. Comparison between the active and the placebo group regarding changes in MRI contrast enhancement in terms of the transfer constant (Ktrans) for the carotid region

    Time frame: MRI scan at enrolment visit and within group after 3 months.

Secondary outcomes

  1. Comparison between the active and the placebo group regarding changes in MRI contrast enhancement measured as fractional plasma volume (Vp) and changes in 18FDG uptake in terms of standardised uptake value (SUV), respectively

    Time frame: MRI scan at enrolment visit and within group after 3 months. 18FDG at randomisation visit (baseline) and within group after 3 months treatment.

  2. Change in carotid MRI contrast enhancement in terms of Ktrans and Vp.

    Time frame: At enrolment visit and within group after 3 months treatment.

  3. Change in 18FDG uptake in terms of SUV.

    Time frame: At randomisation visit (baseline) and within group after 3 months treatment.

07

Study locations

1 site
  • Research Site
    Uppsala, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2008
First posted
Jun 3, 2008
Start
Dec 2007
CompletionActual
Jun 2009
Last update
Jun 30, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00689416
Lead sponsor
AstraZeneca
First posted
Jun 3, 2008
Start date
Dec 2007
Completion
Jun 2009
Last update
Jun 30, 2009

Study contacts

Håkan Ahlström, MD, Professor
principal investigator · Uppsala University Sweden
Maria Leonsson-Zachrissson, MD, Study Physician
study chair · AstraZeneca R&D Mölndal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion